{"abstract":"This notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of a Start-Up Exclusive Evaluation Option License Agreement to practice the inventions embodied in the following Patent Applications to Circumvent Pharmaceuticals Inc. (\"Circumvent\") located in Pasadena, California, USA:","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2016/08/16/2016-19418.html","cfr_references":[],"citation":"81 FR 54581","comment_url":null,"comments_close_on":"2016-08-31","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before August 31, 2016 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2016-19418","effective_on":null,"end_page":54582,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2016/08/16/2016-19418.xml","html_url":"https://www.federalregister.gov/documents/2016/08/16/2016-19418/prospective-grant-of-start-up-exclusive-evaluation-option-license-agreement-small-molecule","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2016-19418?publication_date=2016-08-16","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2016-08-16/2016-19418/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":122,"last_updated":"2026-08-23 22:15:04 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2016-08-16/pdf/2016-19418.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2016-19418.pdf?1471265131","publication_date":"2016-08-16","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2016/08/16/2016-19418.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-03-01T00:32:39Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":54581,"subtype":null,"title":"Prospective Grant of Start-Up Exclusive Evaluation Option License Agreement: Small Molecule Therapeutic Compounds Encompassed Within the Licensed Patent Rights for the Treatment of Thioesterase Deficiency Disorder","toc_doc":"Small Molecule Therapeutic Compounds Encompassed Within the Licensed Patent Rights for the Treatment of Thioesterase Deficiency Disorder","toc_subject":"Prospective Grant of Start-up Exclusive License:","topics":[],"type":"Notice","volume":81}